Treating Benzodiazepine Withdrawal in a Bridge Clinic
- PMID: 38922639
- DOI: 10.1097/ADM.0000000000001334
Treating Benzodiazepine Withdrawal in a Bridge Clinic
Abstract
Background: Benzodiazepine-involved overdose deaths are rising, driven by increasing use of nonprescribed benzodiazepine pills. For patients who wish to stop nonprescribed benzodiazepine use, rapid inpatient tapers are typically the only option to treat benzodiazepine withdrawal. Substance use disorder bridge clinics can provide the high-touch care needed to manage outpatient benzodiazepine tapers in patients at high risk due to other substance use disorders.
Objective: Describe the implementation and short-term outcomes of an outpatient benzodiazepine taper protocol to treat benzodiazepine withdrawal in a substance use disorder bridge clinic.
Methods: The clinical team developed a 4- to 6-week intensive outpatient taper protocol using diazepam. Patients with benzodiazepine use disorder were eligible if they had benzodiazepine withdrawal, lacked a prescriber, wanted to stop benzodiazepines completely, and agreed to daily visits. For patients who initiated a taper between April 2021 and December 2022, we evaluated the proportion of patients who completed a taper (i.e., tapered to a last prescribed dose of diazepam 10 mg/d or less); likelihood of remaining on the taper over time; and seizure, overdose, or death documented at the study institution during or within 1 month of taper completion or discontinuation. Other secondary outcomes included HIV testing and prevention, hepatitis C testing, and referrals to recovery coaching or psychiatry.
Results: Fifty-four patients initiated a total of 60 benzodiazepine tapers. The population was mostly male (61%) and non-Hispanic White (85%). Nearly all patients had opioid use disorder (96%), and most (80%) were taking methadone or buprenorphine for opioid use disorder before starting the taper. Patients reported using multiple substances in addition to benzodiazepines, most commonly fentanyl (75%), followed by cocaine (41%) and methamphetamine (21%). Fourteen patients (23%) completed a taper with a median duration of 34 days (IQR 27.8-43.5). Most tapers were stopped when the patient was lost to follow-up (57%), or the team recommended inpatient care (18%). Two patients had a seizure, and 4 had a presumed opioid-involved overdose during or within 1 month after the last taper visit, all individuals who did not complete a taper. No deaths occurred during or within 1 month of taper completion or discontinuation. Challenges included frequent loss to follow-up in the setting of other unstable substance use. Patients received other high-priority care during the taper including HIV testing (32%), PrEP initiation (6.7%), hepatitis C testing (30%), and referrals to recovery coaches (18%) and psychiatry (6.7%).
Conclusions: Managing benzodiazepine withdrawal with a 4- to 6-week intensive outpatient taper in patients with benzodiazepine and opioid use disorders is challenging. More work is needed to refine patient selection, balance safety risks with feasibility, and study long-term, patient-centered outcomes.
Copyright © 2024 American Society of Addiction Medicine.
Conflict of interest statement
The authors have no conflicts of interest to report.
Similar articles
-
A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal.Clin Toxicol (Phila). 2023 Nov;61(11):941-951. doi: 10.1080/15563650.2023.2285702. Epub 2023 Dec 19. Clin Toxicol (Phila). 2023. PMID: 38112312 Review.
-
Treatment of concurrent etizolam and tianeptine withdrawal following accidental overdose.Ment Health Clin. 2023 Jan 5;12(6):356-359. doi: 10.9740/mhc.2022.12.356. eCollection 2022 Dec. Ment Health Clin. 2023. PMID: 36644586 Free PMC article.
-
Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.JAMA Netw Open. 2022 Sep 1;5(9):e2234168. doi: 10.1001/jamanetworkopen.2022.34168. JAMA Netw Open. 2022. PMID: 36173629 Free PMC article.
-
Benzodiazepine withdrawal in pregnant women with opioid use disorders: An observational study of current clinical practices at a tertiary obstetrical hospital.Gen Hosp Psychiatry. 2019 Mar-Apr;57:29-33. doi: 10.1016/j.genhosppsych.2018.12.005. Epub 2018 Dec 11. Gen Hosp Psychiatry. 2019. PMID: 30669023
-
Buprenorphine for managing opioid withdrawal.Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025. doi: 10.1002/14651858.CD002025.pub5. Cochrane Database Syst Rev. 2017. PMID: 28220474 Free PMC article. Review.
References
-
- Votaw VR, Geyer R, Rieselbach MM, et al. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019;200:95–114.
-
- Liu S, O'Donnell J, Gladden RM, et al. Trends in nonfatal and fatal overdoses involving benzodiazepines—38 States and the District of Columbia, 2019–2020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136–1141.
-
- Kleinman RA, Weiss RD. Benzodiazepine-involved overdose deaths in the USA: 2000–2019. J Gen Intern Med. 2022;37(8):2103–2109.
-
- Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. Published online 2022. Available at: https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-ns.... Accessed February 2, 2024.
-
- Greenblatt HK, Greenblatt DJ. Designer benzodiazepines: A review of published data and public health significance. Clin Pharmacol Drug Dev. 2019;8(3):266–269.
LinkOut - more resources
Full Text Sources
Miscellaneous